口服尼膜同对血管性痴呆患者认知功能及血浆中TXB2和6-Keto-PGF1α含量的影响

Effect of Nimotop on congnitive function and content of TXB2 and 6-Keto-PGF1α in blood plasma of vascular dementia patients

目的评价尼膜同治疗血管性痴呆的临床疗效,并对其作用机制进行相关探索。方法61例VD患者随机分成两组:治疗组31例,口服尼膜同片;对照组30例,口服脑复康片。应用修订简易精神状态量表(MMSE)和日常生活能力(ADL)量表(Barthel指数记分法)评价疗效,同时检测治疗前后患者血浆中TXB2和6-Keto-PGF1α含量的变化。结果与对照组比较治疗组可显著提高MMSE和ADL评分,差异有统计学意义(P<0.05);同时治疗组TXB2和6-Keto-PGF1α含量的变化较对照组亦有显著性差异。结论尼膜同治疗VD安全有效,其作用机制可能与调节血浆中TXB2/6-Keto-PGF1α系统的平衡有关。

[Objective] To assess the efficacy of Nimotop in vascular dementia （VD） and explore the mechanism of action. [Methods] 61 patients with VD were assigned randomly to two groups. 31 patients in the test group were treated with tablet Nimotop and 30 patients in the control group were treated with Naofukang. MMSE and ADL were used to estimate the therapeutic effect. At the same time, the content of TXB2 and 6-Keto-PGF1α in the blood plasma before and after therapy were detected. [Results] Compared with the control group, Nimotop group increased the MMSE and ADL scores strikingly. And there was significant difference between the two groups in the change of the content of TXB2 and 6-Keto-PGF1α in the test group. [Conclusion] Nimotop is safe and effective for VD and the probable mechanism of its action is to adjust the balance of the TXB2/6-Keto-PGF1α system.